Publikasjoner utgått fra NBCG
Gundersen S, Kvinnsland S, Klepp O, Lund E, Host H. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer. 1990 Jan; 26(1): 45-8.
Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Bormer O, Host H. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 1990 Nov; 17(1): 45-50.
Gundersen S, Kvinnsland S, Klepp O, Lund E, Hannisdal E, Host H. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. Eur J Cancer. 1992; 28(2-3): 390-4.
Gundersen S, Hannisdal E, Lundgren S, Wist E. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group. Eur J Cancer. 1994; 30A(12): 1775-8.
Gundersen S, Hannisdal E, Soreide JA, Skarstein A, Varhaug JE.Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Breast Cancer Res Treat. 1995; 36(1): 49-53.
Haarstad H, Lønning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S.
Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. Acta Oncol. 1998;37(4):365-8
Norske brystkreftpublikasjoner
2007
Wiedswang G, Naume B. Can detection of circulating tumor cells in peripheral blood provide prognostic data in breast cancer? Nat Clin Pract Oncol. 2007 Mar;4(3):154-5. Epub 2007 Feb 6. No abstract available.
Bjørn Naume, Xi Zhao, Marit Synnestvedt, Elin Borgen, Hege Giercksky Russnes, Ole Christian Lingjærde, Maria Strømberg, Gro Wiedswang, Gunnar Kvalheim, Rolf Kåresen, Jahn M. Nesland, Anne-Lise Børresen-Dale and Therese Sørlie. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Molecular Oncology. 1: 160-171. 2007.
Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol. 2007 Apr;18(4):694-700. Epub 2007 Feb 13.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6;369(9555):29-36.
Johansen R, Westin AA, Bofin AM, Lundgren S.
Outcome of whole-brain irradiation for breast cancer patients.
Skaane P, Hofvind S, Skjennald A.
Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology. 2007 Sep;244(3):708-17.
Zahl PH, Maehlen J. A decline in breast-cancer incidence. N Engl J Med. 2007 Aug 2;357(5):510-1; author reply 513. No abstract available.
Brustad M, Sandanger TM, Andersen V, Lund E. POP exposure from fish liver consumption and risk of cancer--the Norwegian Women and Cancer Study. J Environ Monit. 2007 Jul;9(7):682-6. Epub 2007 May 18.
Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Lovslett K, Hovig E, Vabo A. Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007 Jul;43(11):1713-7. Epub 2007 Jun 15.
Gjelsvik B, Swensen E, Hjortdahl P. [The general practitioner's view on hormone replacement therapy during and after menopause] Tidsskr Nor Laegeforen. 2007 May 31;127(11):1500-3. Norwegian.
Vatten LJ. [Mammography screening--time for evaluation?] Tidsskr Nor Laegeforen. 2007 May 31;127(11):1492. Norwegian. No abstract available.
Maskarinec G, Takata Y, Chen Z, Gram IT, Nagata C, Pagano I, Hayashi K, Arendell L, Skeie G, Rinaldi S, Kaaks R. IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer. 2007 Oct 15;121(8):1786-92.
Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer. 2007 Sep 1;121(5):1017-20.
Norum J, Olsen JA, Wist EA, Lonning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 2007;46(2):153-64.
Vatten LJ, Forman MR, Nilsen TI, Barrett JC, Romundstad PR. The negative association between pre-eclampsia and breast cancer risk may depend on the offspring's gender. Br J Cancer. 2007 May 7;96(9):1436-8. Epub 2007 Mar 27.
Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study. Int J Cancer. 2007 Aug 1;121(3):645-8.
Lie JA, Andersen A, Kjaerheim K. Cancer risk among 43000 Norwegian nurses. Scand J Work Environ Health. 2007 Feb;33(1):66-73.
Vistad I, Fossa SD, Kristensen GB, Mykletun A, Dahl AA. The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample. J Womens Health (Larchmt). 2007 Jan-Feb;16(1):139-48.
Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lonning PE, Borresen-Dale AL, Kristensen VN. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics. 2007 Feb;17(2):127-36.
Bjorvatn C, Eide GE, Hanestad BR, Oyen N, Havik OE, Carlsson A, Berglund G. Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer. J Genet Couns. 2007 Apr;16(2):211-22.
Skaane P, Kshirsagar A, Stapleton S, Young K, Castellino RA. Effect of computer-aided detection on independent double reading of paired screen-film and full-field digital screening mammograms. AJR Am J Roentgenol. 2007 Feb;188(2):377-84.
Zahl PH, Maehlen J. Constant relative survival rates in Sweden and Norway when adjusting for screening-related overdiagnosis. Int J Cancer. 2007 May 15;120(10):2279; author reply 2280. No abstract available.
Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa SD, Travis LB. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007 Nov;105(3):359-68. Epub 2007 Jan 13.
Bremnes Y, Irland Australia Tyskland Østerrike Sveits Belgia Spania short Message Service (SMS) is a communications protocol allowing the interchange of short text messages between mobile telephone devices. SMS text messaging is the most widely used data application on the planet, with 2.4 billion active users, or 74% of all mobile phone subscribers sending and receiving text messages on their phones. The SMS technology has facilitated the development and growth of text messaging. The connection between the phenomenon of text messaging and the underlying technology is so great that in parts of the world the term "SMS" is used as a synonym for a text message or the act of sending a text message, even when a different protocol is being used. Portugal Tsjekkiske republikk Nederland Sverige Sør-Afrika Norge Malaysia Danmark Estland short Message Service (SMS) is a communications protocol allowing the interchange of short text messages between mobile telephone devices. SMS text messaging is the most widely used data application on the planet, with 2.4 billion active users, or 74% of all mobile phone subscribers sending and receiving text messages on their phones. The SMS technology has facilitated the development and growth of text messaging. The connection between the phenomenon of text messaging and the underlying technology is so great that in parts of the world the term "SMS" is used as a synonym for a text message or the act of sending a text message, even when a different protocol is being used. Polen USA Slovakia SMS GratisSMS GratuitSMS GratisSMS darmoweSMSSMS gratisSMS GratisSMS FreeSMS FreeSMS FreeDirectorySMS GratisJavaHotelsBanksCarsSoftwareEstateHaulierHotelsPubTaxiSMS gratis short Message Service (SMS) is a communications protocol allowing the interchange of short text messages between mobile telephone devices. SMS text messaging is the most widely used data application on the planet, with 2.4 billion active users, or 74% of all mobile phone subscribers sending and receiving text messages on their phones. The SMS technology has facilitated the development and growth of text messaging. The connection between the phenomenon of text messaging and the underlying technology is so great that in parts of the world the term "SMS" is used as a synonym for a text message or the act of sending a text message, even when a different protocol is being used. SMS GratisSageTranslationPop3SageSMS GratisSMS GratisSMS GratisSMS GratisSMS FreeFind UKDNS Belge Sage SMS Gratis DNS GratisCash Back Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Insulin-like growth factor and mammographic density in postmenopausal Norwegian women. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):57-62.
Hofvind S, Bjurstam N, Sorum R, Bjorndal H, Thoresen S, Skaane P. Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme. J Med Screen. 2006;13(4):192-6.
Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer. 2007 Feb 15;120(4):880-4.
2006
Geisler J., Lønning PE. Aromatase inhibitors as adjuvant treatment of breast cancer. Crit Rev Oncol Hematol 57:53-61, 2006
Geisler J, Lønning PE. Clinical pharmacology of aromatase inhibitors. Book chapter; Milestones in Drug Therapy: Aromatase Inhibitors. Ed: Furr BJA. Series: Milestones in Drug Therapy (Serial Editors Parnham MJ and Bruinvels J). ISBN 3-7643-7199-4 Birkhäuser Verlag, Basel, Boston, Berlin, pages 45-52, 2006
Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 17:217-225, 2006
Huszthy PC, Brekken C, Pedersen TB, Thorsen F, Sakariassen PØ, Skaftnesmo KO, Haraldseth O, Lønning PE, Bjerkvig R, Enger PØ. Local delivery of species-specific endostatin improves anti-tumor efficacy. J Neurosurg 104:118-128, 2006
Lønning PE. Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Mini- Review. Breast Cancer Online 9 (1)e3.doi:10.1017/S1470903106004731 (Publ Online January 3), 2006
Kristensen VN, Tsalenko A, Geisler J, Faldaas A, Grenaker, Lingjaerde OC, Fjeldstad S, Yakhini Z, Lønning PE, Børresen-Dale A-L. Multilocus analysis of SNP and metabolic data within a given pathway. BMC Genomics 7: art 5, Jan 13, 2006
Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen H, Aarseth JH, Vedeler CA. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53-58, 2006
Muggerud AA, Johnsen H, Barnes D, Steel A, Lønning PE, Naume B, Sørlie T, Børresen-Dale A-L. Evaluation of metrigenix custom 4D arrays applied for detection of breast cancer sub-types. BMC Cancer 6:59-; doi:10.1186/1471-2407-6-59; 2006
Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen H, Drivsholm L, Aarseth JH, Vedeler CA. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 55: 1280-84, 2006
Kristensen V, Edvardsen H, Tsalenko A, Nordgard S, Sørlie T, Sharan R, Vailaya A, Ben-Dor A, Lønning PE, Lien S, Omholt S, Syvanen A-C, Yakhini Z, Børresen-Dale A-L. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci 103:7735-7740, 2006
Smith IE, Dowsett M, Yap Y-S, Walsh G, Lønning PE, Santen RJ, Hayes D. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amerrhoea caution and suggested guidelines. J Clin Oncol 24:2444-2447, 2006
Lønning PE, Geisler J. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology 3: 357, 2006
Thorsen F, Afione S, Huszthy PA, Tysnes BB, Svendsen A, Bjerkvig R, Kotin RM, Lønning PE, Hoover F. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. J Gene Med 8:1131-40,2006
Bøe SO, Haave M, Grudic A, Bjerkvig R, Lønning PE. Promyelocytic leukemia-nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci 119:3284-95, 2006
Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lønning PE, Tibshirani R, Børresen-Dale A-L, Pollack JR. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes and Cancer 45:1033-40,2006
Lønning PE. Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 16(Suppl 2):518-20, 2006
Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer 45:1155-63, 2006.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Børresen-Dale AL, Lillehaug J, Lønning PE. The novel p21 polymorphism p21 G251A is associated with locally advanced breast cancer. Clin Cancer Res 12: 6000-6004, 2006.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Øfjord SE, Polli A, Di Salle E, Paolini J. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomized, placebo-controlled study. Eur J Cancer 42: 2968-75, 2006.
Baumbusch L, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Domreiter I, Børresen-Dale A-L. Expression of full-length p53 and its isoform ?p53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer:5: doi:10.1186/1476-4598-5-47, 2006
Gro Wiedswang, Elin Borgen, Cecilie Schirmer, Rolf Kåresen, Gunnar Kvalheim, Jahn M. Nesland, Bjørn Naume. Clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2006: 2013-19.
Therese Sorlie, Yulei Wang, Chunlin Xiao, Hilde Johnsen, Bjørn Naume, Raymond R Samaha and Anne-Lise Borresen-Dale Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer. Gene expression analyses across three different platforms. BMC Genomics. 2006 May 26;7:127
Muggerud AA, Johnsen H, Barnes DA, Steel A, Lonning PE, Naume B, Sorlie T, Borresen-Dale AL. Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes.BMC Cancer. 2006 Mar 15;6:59
Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006 Sep 1;107(5):885-92
Adjuvant behandling med trastuzumab ved tidlig stadium brystcancer. Rapport fra Kunnskapssenteret. K. Johansen, P.E. Lønning, B. Naume, J. Norum, J.A. Olsen, E. Wist. Nr. 2-2006. ISBN 82-8121-084-2.
Adjuvant behandling med trastuzumab ved tidlig stadium brystcancer. En helseøkonomisk analyse. Rapport fra Kunnskapssenteret. K. Johansen, P.E. Lønning, B. Naume, J. Norum, J.A. Olsen, E. Wist. Nr. 18-2006. ISBN 82-8121-112-1.
Borgen E, Pantel K, Schlimok G, Müller P, Renolen A, Ehnle S, Coith C, Nesland JM and Naume B. A European Interlaboratory testing of three wee-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom. 2006 Nov 15;70(6):400-9.
Hicks J, Krasnitz A, Muthuswamy L, Navin N, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, Reiner A, Healy J, Wigler M, Børresen-Dale AL,
Naume B, Schlichting E, Norton L, Maner S, Lundin P, Zetterberg A. Genome profiles and survival in breast cancer. Genome Res. 2006 Dec;16(12):1465-79.
2005
Bakken K. Lund E. Eggen AE. The impact of hormone replacement therapy on the incidence of breast cancer in Norway. Journal of Clinical Oncology. 23(15):3636-7; author reply 3637-8, 2005 May 20.
Lønning PE. Chemosesitization. Book chapter, Curiel DT, Douglas JT (Eds); Humana Press, Totowa, New Jersey, Cancer Gene Therapy 335-48, 2005
Lønning PE, Sørlie T, Børresen-Dale, A-L. Genomics in breast cancer – therapeutic implications? Nature Clin Practise Oncology 2: 26-33, 2005
Kristensen VN, Sørlie T, Geisler J, Langerød A, Yoshimura N, Kåresen R, Harada N, Faldaas A,, Lønning PE, Børresen-Dale A-L. Gene expression profiling of breast cancer in relation to estriogen receptor status and estrogen-metabolizing enzymes: clinical implications. Clin Cancer Res 11:878-883, 2005
Lønning PE. Exemestane for Breast Cancer Prevention – a Feasible Strategy? Clin Cancer Res 11:918s-924s, 2005
Aas T, Geisler S, Helle H, Børresen-Dale A-L, Lønning PE, Akslen LA. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncol Rep 13:525-530, 2005
Lønning PE. Antiendocrine drugs used in cancer treatment. Bookchapter; Cancer Clinical Pharmacology, Schellens JHM, McLeod HL, Newell DR (eds) Oxford University Press, Vol 1, 216-237, 2005
Helle SI, Mietlowski W, Guastalla J, Szakolczai I, Bajetta E, Sommer H, Baltali E, Pinter T, Csepreghy M, Ottestad L, Boni C, Bryce C, Klijn J, Lønning PE. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen montotherapy. Eur J Cancer 41:694-701, 2005
Lønning PE. Aromatase inhibitors for breast cancer therapy (Norw language: Aromatasehemmere i behandling av brystkreft). Tidsskr N Legef (J Norw Med Assoc)125:723-728, 2005
Joensuu H, Ejlertsen B, Lønning PE, Rutqvist L-E. Aromatase inhibitors in the treatment of early and advanced breat cancer. Acta Oncol. 44:23-31, 2005
Kristensen VN, Sørlie T, Geisler J, Yoshimura N, Linegjærde OC, Glad I, Frigessi A, Harada N, Lønning PE, Børresen-Dale AL. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. J Steroid Biochem Mol Biol 95:105-111, 2005
Come SE, Buzdar AU, Ingle JN, Arteage CL, Brodie AM, Colditz GA, Johnston SRD, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart C. Proceedings of the fourth international conference on recent advances and future directions in endocrine therapy for breast cancer: Conference summary statement. Clin Cancer Res 11:861-864, 2005
Lønning PE, Geisler J. Aromatase inhibitors – socio-economical issues. J Steroid Biochem Molec Biol 95:137-142, 2005
Huszthy PC, Svendsen A, Wilson JM, Halbert C, Miller AD, Lønning PE, Bjerkvig R, Hoover F. Widespread dispersion of adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma mulltiforme xenografts. Hum Gene Ther 16:381-92, 2005
Geisler J, Lønning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Molec Biol 95:75-81, 2005
Geisler J, Lønning PE. Aromatase inhibition – translation into a successful therapeutic approach. Clin Cancer Res. 11:2809-2821, 2005
Jeffrey SS, Lønning PE, Hillner BE. Genomics-based prognosis and prediction in breast cancer. J Natl Comprehensive Cancer Network 3:291-300, 2005
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Øfjord SE, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkesr and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005
Geisler J, Haynes B, Anker G, Helle H, Ekse D, Dowsett M, Lønning PE. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. J Steroid Biochem Molec Biol 96:415-422, 2005
Moller B. Weedon-Fekjaer H. Hakulinen T. Tryggvadottir L. Storm HH. Talback M. Haldorsen T. The influence of mammographic screening on national trends in breast cancer incidence. European Journal of Cancer Prevention. 14(2):117-28, 2005 Apr.
Jugessur A. Apold J. Heimdal K. Aloysius T. Eliassen AK. Fauske L. Matre G. Eiken HG. Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway. Disease Markers. 21(1):29-36, 2005.
Haldorsen T. Tynes T. Cancer in the Sami population of North Norway, 1970-1997. European Journal of Cancer Prevention. 14(1):63-8, 2005 Feb.
Robsahm TE. Tretli S. Weak associations between sociodemographic factors and breast cancer: possible effects of early detection. European Journal of Cancer Prevention. 14(1):7-12, 2005 Feb.
Zahl PH. Maehlen J. [Estrogen replacement therapy and breast cancer].Tidsskrift for Den Norske Laegeforening. 125(8):1045; author reply 1045, 2005 Apr 21.
Bakken K. Alsaker E. Eggen AE. Lund E. [Estrogen replacement therapy and breast cancer]. Tidsskrift for Den Norske Laegeforening. 125(3):282-5, 2005 Feb 3.
Gram IT. Braaten T. Terry PD. Sasco AJ. Adami HO. Lund E. Weiderpass E. Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiology, Biomarkers & Prevention. 14(1):61-6, 2005 Jan.
Furberg AS. Jasienska G. Bjurstam N. Torjesen PA. Emaus A. Lipson SF. Ellison PT. Thune I. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiology, Biomarkers & Prevention. 14(1):33-40, 2005 Jan.
Margolis KL. Mucci L. Braaten T. Kumle M. Trolle Lagerros Y. Adami HO. Lund E. Weiderpass E. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. [Journal Article] Cancer Epidemiology, Biomarkers & Prevention. 14(1):27-32, 2005 Jan.
Nord C. Mykletun A. Thorsen L. Bjoro T. Fossa SD. Self-reported health and use of health care services in long-term cancer survivors. International Journal of Cancer. 114(2):307-16, 2005 Mar 20.
Sudmann A. Skarre E. Talleraas O. Norstein J. [Breast-conserving surgery and sentinel node procedure in Norway, 1993-2001]. Tidsskrift for Den Norske Laegeforening. 125(5):556-9, 2005 Mar 3.
Karesen R. [Breast cancer surgery in Norway]. Tidsskrift for Den Norske Laegeforening. 125(5):555, 2005 Mar 3.
Vatten LJ. Nilsen TI. Tretli S. Trichopoulos D. Romundstad PR. Size at birth and risk of breast cancer: prospective population-based study. International Journal of Cancer. 114(3):461-4, 2005 Apr 10.
Albrektsen G. Heuch I. Hansen S. Kvale G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. British Journal of Cancer. 92(1):167-75, 2005 Jan 17.
Stephan Braun and Bjørn Naume. Circulating and disseminated tumor cells. J Clin Oncol. 2005 Mar 10;23(8):1623-6.
Stephan Braun, Florian D. Vogl, Bjørn Naume, Wolfgang Janni,Michael P. Osborne, R. Charles Coombes, Guenter Schlimok, Ingo J. Diel, Bernd Gerber, Gerhard Gebauer, Jean-Yves Pierga, Christian Marth, Daniel Oruzio, Gro Wiedswang, Erich-Franz Solomayer, Guenther Kundt, Barbara Strobl, Tanja Fehm, George Y. C. Wong, Judith Bliss, Anne Vincent-Salomon, and Klaus Pantel, for the Pooled Analysis Study Group. International Pooled Analysis of Prognostic Significance of Bone Marrow Micrometastasis in Patients with Stage I, II, or III Breast Cancer. New England Journal of Medicine, 2005;353:793-802.
2004
Hammerstrom J. Aasland IL. Telhaug R. Moen T. Lodemel B. Sorum Y. Brudevold R. Herlofsen O. Sorbo JH. Almvik T. Lamvik J. High-dose treatment with autologous stem cell support in a Norwegian region.see comment. Norwegian Tidsskrift for Den Norske Laegeforening. 124(19):2498-500, 2004 Oct 7.
Lønning PE. Role of endocrine therapy in breast cancer – where are we going?. Baillieres Best Pract Res; Clin Endocrinol Metab 18:vii-ix, 2004
Lønning PE. Oestrogen suppression; lessons from clinical studies. Baillieres Best Pract Res; Clin Endocrinol Metab 18:33-45, 2004
Lønning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 10:113-118, 2004
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones S, Alvarez I, Bertelli G, Ortman O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Coocconi C, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
Lønning PE. Aromatase inhibitors in breast cancer. End Rel Cancer 11:179-189, 2004
Staalesen V, Leirvaag B, Lillehaug J, Lønning PE. Genetic and epigenetic changes in p21 and p21B do not correlate to doxorubcin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res 10:3438-3443, 2004
Lønning PE and Helle SI. IGF-1 and breast cancer.. Book chapter;. Bock G, Goode J, (Eds), Wiley J & Sons, Chichester, UK, Biology of IGF-1, 205-212 (Discussion: 212-214), 2004
Troester MA, Hoadley KA, Sørlie T, Børresen-Dale A-L, Lønning PE, Herbert B-S, Jerry W. Shay JW, Perou CM. Cell-Type Specific responses to chemotherapeutics in breast cancer. Cancer Res 64: 4218-4226, 2004
Jul-Larsen Å, Visted T, Karlsen BO, Rinaldo CH, Bjerkvig R, Lønning PE, Bøe SO, PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Exp Cell Res 298: 58-73, 2004
Lønning PE. Understanding chemoresistance - the ultimate challenge in cancer therapy. Breast Cancer Online (BCO); vol 7, issue 4, 2004
Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, OH DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale A-L, Perou CM. Mutation of GATA3 in human breast tumors. Oncogene 23: 7669-7678, 2004
Staalesen V, Falck J, Geisler S, Bartkova J, Børresen-Dale A-L, Lukas J, Lillehaug J, Bartek J, Lønning PE. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23: 8535-8544, 2004
Lien EA, Ueland PM, Lønning PE. Letter JNCI. 96:884, 2004
Sørlie T, Børresen-Dale A-L, Lønning PE, Brown PO, Botstein D. Expression profiling of breast cancer: from molecular portraits to clinical utility. Book chapter; Oncogenomics: Molecular approaches to cancer. (Ed: Brenner C. and Duggan DJ). Wiley Publ, New Jersey, 77-100, 2004
Weiderpass E. Braaten T. Magnusson C. Kumle M. Vainio H. Lund E. Adami HO. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 13(7):1121-7, 2004 Jul.
Zahl PH. Maehlen J. Overdiagnosis in mammography screening.see comment. Norwegian Tidsskrift for Den Norske Laegeforening. 124(17):2238-9, 2004 Sep 9.
Hofvind S. Thoresen S. Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer. 101(7):1501-7, 2004 Oct 1.
Hofvind S. Wang H. Thoresen S. Do the results of the process indicators in the Norwegian Breast Cancer Screening Program predict future mortality reduction from breast cancer?. Acta Oncologica. 43(5):467-73, 2004.
Bakken K. Alsaker E. Eggen AE. Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. International Journal of Cancer. 112(1):130-4, 2004 Oct 20.
Dumeaux V. Lund E. Hjartaker A. Use of oral contraceptives, alcohol, and risk for invasive breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 13(8):1302-7, 2004 Aug.
Tjemsland L. Soreide JA. Operable breast cancer patients with diagnostic delay--oncological and emotional characteristics. European Journal of Surgical Oncology. 30(7):721-7, 2004 Sep.
Furberg AS. Veierod MB. Wilsgaard T. Bernstein L. Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. Journal of the National Cancer Institute. 96(15):1152-60, 2004 Aug 4.
Tindholdt TT. Tonseth KA. Solberg US. Mesic H. Busic V. Begic A. [Breast reconstruction following mastectomy]. Tidsskrift for Den Norske Laegeforening. 124(12):1629-32, 2004 Jun 17.
Reed W. Bohler PJ. Sandstad B. Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast Journal. 10(3):174-80, 2004 May-Jun.
Braaten T. Weiderpass E. Kumle M. Adami HO. Lund E. Education and risk of breast cancer in the Norwegian-Swedish women's lifestyle and health cohort study. [ ] International Journal of Cancer. 110(4):579-83, 2004 Jul 1.
Kliukiene J. Tynes T. Andersen A. Residential and occupational exposures to 50-Hz magnetic fields and breast cancer in women: a population-based study. American Journal of Epidemiology. 159(9):852-61, 2004 May 1.
Zahl PH. Strand BH. Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 328(7445):921-4, 2004 Apr 17.
Wist EA. Sommer HH. Ostenstad B. Risberg T. Fjaestad K. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.[see comment]. Acta Oncologica. 43(1):11-4, 2004.
Wist EA. Sommer HH. Ostenstad B. Risberg T. Bremnes Y. Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncologica. 43(2):186-9, 2004.
Bjørn Naumea2, Gro Wiedswangb, Elin Borgenc, Gunnar Kvalheima, Rolf Kåresenb, Hanne Qvistd, Jan Janbue, Torstein Harbitzf and Jahn M Neslandc.
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients. Evaluation of morphological categories and the number of clinically significant cells1. Clin. Cancer Res. 2004. 10: 3091-97.
Bjørn Naume1, Elin Borgen2, Susanne Tøssvik2, Nancy Pavlak3, Diane Oates3, Jahn M. Nesland. Detection of Isolated Tumor Cells in Peripheral Blood and in Bone Marrow. Evaluation of a New Enrichment Method. Cytotherapy. 2004. 6: 244-52.
Gro Wiedswang, Elin Borgen, Rolf Kåresen, Hanne Qvist, Jan Janbu, Gunnar Kvalheim, Jahn M Nesland and Bjørn Naume. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease Free Breast Cancer Patients Predict Unfavorable Clinical Outcome. Clin. Cancer Res. 2004. 10: 5342-48.
2003
Sauer T. Myrvold K. Lomo J. Anderssen KY. Skaane P. Fine-needle aspiration cytology in nonpalpable mammographic abnormalities in breast cancer screening: results from the breast cancer screening programme in Oslo 1996-2001. Breast. 12(5):314-9, 2003 Oct.
Aas T, Geisler S, Eide GE, Faksvåg-Haugen D, Varhaug JE, Bassøe AM, Thorsen T, Børresen-Dale A-L, Akslen LA, Lønning PE. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 39:438-446, 2003
Lønning PE. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 4:177-185, 2003
Lønning PE. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin Pharmacokinet 42:619-631, 2003
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale A-L, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100:8418-8423,2003
Lønning PE. Comparison between aromatase inhibitors and sequential use. J Steroid Biochem Molec Biol 86:275-282, 2003
Geisler S, Børresen-Dale A-L, Anker G, Aas T, Johnsen T, Akslen L, Helle SI, Lønning PE. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582-5588, 2003
Lønning PE, Geisler J, Bhatnagar A. Development of aromatase inhibitors and their pharmacological profile. Am J Clin Oncol 26:s3-s8, 2003
Kristiansen M, Helland Å, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale A-L, Ørstavik KH. X chromosome inactivation in cervical cancer patients. Cancer Genet Cytogenet 146:73-76, 2003
Lønning PE, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 30:23-32, 2003
Lønning PE. Aromatase inhibitors for treatment of breast cancer (Norwegian Language) J Norwegian Pharm Soc; vol 111:16-18, 2003.
Mackenbach JP. Bos V. Andersen O. Cardano M. Costa G. Harding S. Reid A. Hemstrom O. Valkonen T. Kunst AE. Widening socioeconomic inequalities in mortality in six Western European countries.[see comment]. [. Multicenter Study] International Journal of Epidemiology. 32(5):830-7, 2003 Oct.
Heimdal K. Maehle L. Apold J. Pedersen JC. Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. [. Multicenter Study] European Journal of Cancer. 39(15):2205-13, 2003 Oct.
Brandberg Y. Michelson H. Nilsson B. Bolund C. Erikstein B. Hietanen P. Kaasa S. Nilsson J. Wiklund T. Wilking N. Bergh J. Scandinavian Breast Group Study 9401. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.[see comment]. [Clinical Trial. . Multicenter Study. Randomized Controlled Trial] Journal of Clinical Oncology. 21(19):3659-64, 2003 Oct 1.
Bukholm IR. Husdal A. Nesland JM. Langerod A. Bukholm G. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. [. Multicenter Study] Breast Cancer Research & Treatment. 80(2):199-206, 2003 Jul.
Reed W. Hannisdal E. Skovlund E. Thoresen S. Lilleng P. Nesland JM. Pregnancy and breast cancer: a population-based study. Virchows Archiv. 443(1):44-50, 2003 Jul.
Kliukiene J. Tynes T. Andersen A. Follow-up of radio and telegraph operators with exposure to electromagnetic fields and risk of breast cancer. European Journal of Cancer Prevention. 12(4):301-7, 2003 Aug.
Hofvind SS. Wang H. Thoresen S. The Norwegian Breast Cancer Screening Program: re-attendance related to the women's experiences, intentions and previous screening result. Cancer Causes & Control. 14(4):391-8, 2003 May.
Karesen R. Hervik A. Schlichting E. [Medical logistics: principles applied to diagnostics and therapy in women with symptoms and signs of breast cancer]. [Norwegian] Tidsskrift for Den Norske Laegeforening. 123(12):1687-90, 2003 Jun 12.
Brustugun OT. Nome O. Bruland S OS. Ottestad L. Lilleby W. [Breast cancer patients' assessment of waiting time before radiotherapy]. [Norwegian] Tidsskrift for Den Norske Laegeforening. 123(12):1685-6, 2003 Jun 12.
Mjaaland I. Dybvik H. Heikkil R. Nysted A. [Radiotherapy after breast-conserving surgery in the treatment of breast cancer: early results from a non-university hospital in Norway]. [Norwegian] Tidsskrift for Den Norske Laegeforening. 123(12):1683-4, 2003 Jun 12.
Dumeaux V. Alsaker E. Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. International Journal of Cancer. 105(6):844-50, 2003 Jul 20.
Kravdal O. Children, family and cancer survival in Norway. International Journal of Cancer. 105(2):261-6, 2003 Jun 10.
Heuch I. Jacobsen BK. Kvale G. Breast cancer and breastfeeding.[comment]. [Comment. Letter] Lancet. 361(9352):176; author reply 177, 2003 Jan 11.
Wiedswang, G., E. Borgen R, Kåresen and Naume, B. Detection of isolated tumour cells in bone marrow from breast cancer patients. The significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analysed. Cytotherapy. 2003. 5:40-45.
Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T and B. Naume. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003. 21:3469-78.
2002
Bernstein JL, Seminara D, Borresen-Dale AL. Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002.
Breast Cancer Res. 2002;4(6):249-52.
Geisler J, Haines B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-57, 2002
Lønning PE, Geisler J, Dowsett M. Endocrine effects of nonsteriodal aromatase inhibitors and their clinical impact – reply. J Clin Oncol 20:3040-40, 2002
Geisler J, Dowsett M, Lønning PE. Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. Am J Oncol Rev 1:99-102, 2002
Lønnng PE. Overview of aromatase inhibitors and inactivators in the treatment of advanced breast cancer. Bookchapter. “Endocrine Therapy in Breast Cancer” by Miller, WR and Ingle, JN (Eds). Marcel Dekker Inc., New York, p33-46, 2002
Lønning PE. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs and Aging 19:277-98,2002
Helle SI, Ekse D, Holly JMP, Lønning PE. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. J. Steroid Biochem Molec Biol 81:95-102,2002
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning PE, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Bruke K, Eisenberg P. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73:161-75, 2002
Lønning PE. The role of aromatase inactivators in the treatment of breast cancer. Int J Clin Oncol 7:265-270 ,2002
Enger PØ, Thorsen F, Lønning PE, Bjerkvig R, Hoover F. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum Gene Ther 13:1115-1125, 2002
Lønning PE. Aromatase inhibitors and inactivators for breast cancer treatment. Eur J Cancer 38(Suppl 6):s47-s48, 2002
Pollack J, Sørlie T, Perou C, Rees C, Jeffrey SJ, Lønning PE, Tibshirani R, Botstein D,Børresen-Dale A-L, Brown, P. Microarray analysis of DNA copy number alterations and their relationship to mRNA levels in human breast cancer. Proc Natl Acad Sci 99:12963-12968, 2002
Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R.Pre-eclampsia in pregnancy and subsequent risk for breast cancer.
Br J Cancer. 2002 Oct 21;87(9):971-3.
Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E.Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1375-81.
Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaloy S.Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
Ann Oncol. 2002 Nov;13(11):1786-91.
Landmark BT, Wahl A.Living with newly diagnosed breast cancer: a qualitative study of 10 women with newly diagnosed breast cancer.
J Adv Nurs. 2002 Oct;40(1):112-21.
Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pregnancy related protection against breast cancer depends on length of gestation.
Br J Cancer. 2002 Jul 29;87(3):289-90.
Heimdal K, Skovlund E, Moller P.Oral contraceptives and risk of familial breast cancer.
Cancer Detect Prev. 2002;26(1):23-7.
Zahl PH, Strand BH.[Does organized mammographic screening reduce the breast cancer mortality?]
Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):551; author reply 551. Norwegian.
Robsahm TE, Tretli S. Breast cancer incidence in food- vs non-food-producing areas in Norway: possible beneficial effects of World War II.
Br J Cancer. 2002 Feb 1;86(3):362-6.
Wang H, Hofvind S, Tretli S, Thoresen S, Langmark F. [Does organized mammographic screening reduce breast cancer mortality? The Cancer Registry's view on the current debate]
Tidsskr Nor Laegeforen. 2002 Jan 20;122(2):211-3. Norwegian.
Pedersen K, Nordanger J.Quality control of the physical and technical aspects of mammography in the Norwegian breast-screening programme.
Eur Radiol. 2002 Feb;12(2):463-70.
Vatten LJ, Maehle BO, Lund Nilsen TI, Tretli S, Hsieh CC, Trichopoulos D, Stuver SO. Birth weight as a predictor of breast cancer: a case-control study in Norway.
Br J Cancer. 2002 Jan 7;86(1):89-91.
2001
Pedersen K, Nordanger J. Quality control of the physical and technical aspects of mammography in the Norwegian breast-screening programme.
Eur Radiol. 2002 Feb;12(2):463-70.
Lønning PE, Geisler J, Johannessen DC, Gschwind H-P, Waldmeier F, Schneider W, Galli B, Winkler T, Blum W, Kriemler H-P, Miller WR, Faigle JW. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Molec Biol 77:39-47, 2001
Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, Mella O, Howell T. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treatment 67:111-116, 2001
Geisler S, Lønning PE, Aas T, Johnsen H, Fluge Ø, Faksvaag-Haugen D, Lillehaug J, Akslen L., Børresen-Dale A-L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505-2512, 2001
Helle SI, Ueland T, Ekse D, Frøland SS, Holly, JMP, Lønning PE, Aukrust P. The insulin-like growth factor-system in human immunodeficiency virus infestion: relations to immunological parameters, disease progression and anti-retroviral therapy. J Clin Endocrinol Metab 86:227-233, 2001
Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Lønning PE. Influence of neoadjuvant anastrozole (Arimidex1) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7:1230-36, 2001
Geisler J, Lønning PE. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow’s challenges. Clin Breast Cancer 1:297-308, 2001
Jain AN, Chin K, Børresen-Dale A-L, Erikstein, BK, Lønning PE, Kaaresen R, Gray J. Quantitative analysis of chromosomal CGH in human breast tumors links loci with patient survival and tumor phenotype. Proc Natl Acad Sci 98:7952-7957, 2001.
Lønning PE. Exemestane: a review of its clinical efficacy and safety. Breast 10:198-208, 2001
Helle SI, Geisler J, Aas T, Paulsen T, Holly JMP, Lønning PE. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. Brit J Cancer 85:74-77, 2001
Helle SI, Geisler J, Anker GB, Leirvaag B, Holly JMP, Lønning PE. Alterations in the insulin-like growth factor-system during treatment with diethylstilbestrol in patients with metastatic breast cancer. Brit J Cancer 85:147-151, 2001
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Rees CA, Brown PO, Botstein D, Lønning PE, Børresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. Proc Natl Acad Sci 98:10869-10874, 2001
Lønning PE, Sørlie T, Perou C, Brown P, Botstein D, Børresen-Dale A-L. Microarrays in primary breast cancer – lessons from chemostherapy studies. End Rel Cancer 8:259-263, 2001
Lønning PE. Aromatase inhibitors and inactivators in breast cancer. Brit Med J: 323: 880–881, 2001
Lønning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Slichting E, Geisler J. The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res 7(Suppl):4423s-4428s, 2001
Lønning PE. Step-wise oestrogen suppression manipulating the oestrostat. J Steroid Bioch Mol Biol 79:127-132, 2001
Levin T, Reichelt J, Heimdal K, Moller P.[Information to families with hereditary breast and ovarian cancer]
Tidsskr Nor Laegeforen. 2001 Nov 20;121(28):3292-4. Norwegian.
Norum J.Evaluation of Norwegian cancer hospitals web sites and explorative survey among cancer patients on their use of the internet.
J Med Internet Res. 2001 Oct-Dec;3(4):E30.
Wang H, Bjurstam N, Bjorndal H, Braaten A, Eriksen L, Skaane P, Vitak B, Hofvind S, Thoresen SO.Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT.
Int J Cancer. 2001 Nov;94(4):594-8.
Moller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L; Norwegian Inherited Breast Cancer Group; Norwegian Inherited Ovarian Cancer Group.
Genetic epidemiology of BRCA1 mutations in Norway.Eur J Cancer. 2001 Dec;37(18):2428-34.
Lundgren S, Jorgensen S, Karesen R.[Breast cancer surgery in Norway 1990-95 illustrated by data from SINTEF United]
Tidsskr Nor Laegeforen. 2001 Sep 30;121(23):2688-93. Norwegian.
Strand BH, Zahl PH. [When will mammography screening reduce breast cancer mortality?] Tidsskr Nor Laegeforen. 2001 Aug 30;121(20):2390-2. Norwegian.
Nilsen TI, Vatten LJ.Adult height and risk of breast cancer: a possible effect of early nutrition. Br J Cancer. 2001 Sep 28;85(7):959-61.
Hjartaker A, Laake P, Lund E.Childhood and adult milk consumption and risk of premenopausal breast cancer in a cohort of 48,844 women - the Norwegian women and cancer study.
Int J Cancer. 2001 Sep;93(6):888-93.
Haldorsen T, Reitan JB, Tveten U.Cancer incidence among Norwegian airline cabin attendants.Int J Epidemiol. 2001 Aug;30(4):825-30.
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A.Risk factors for male breast cancer--a case-control study from Scandinavia.
Acta Oncol. 2001;40(4):467-71.
Zahl PH, Kopjar B, Maehlen J.[Norwegian breast cancer mortality rates and validity of Swedish mammographic studies]
Tidsskr Nor Laegeforen. 2001 Jun 20;121(16):1928-31. Norwegian.
Hofvind SS, Thoresen SO.[Physical activity and breast cancer] Tidsskr Nor Laegeforen. 2001 Jun 20;121(16):1892-5. Norwegian.
Backe B, Hunskaar S.Increased acceptance of HRT and improved level of information: a change in Norwegian women's opinion from 1990 to 1997.
Acta Obstet Gynecol Scand. 2001 Jul;80(7):623-7.
Landmark BT, Strandmark M, Wahl AK.Living with newly diagnosed breast cancer--the meaning of existential issues. A qualitative study of 10 women with newly diagnosed breast cancer, based on grounded theory.
Cancer Nurs. 2001 Jun;24(3):220-6.
Moller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L; Norwegian Inherited Breast Cancer Group; Norwegian Inherited Ovarian Cancer Group.
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Eur J Cancer. 2001 May;37(8):1027-32.
Wang H, Karesen R, Hervik A, Thoresen SO.Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening.
Cancer Causes Control. 2001 Jan;12(1):39-45.
Kliukiene J, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment.
Br J Cancer. 2001 Feb 2;84(3):397-9.
Rosvold EO, Hjartaker A, Bjertness E, Lund E. Breast self-examination and cervical cancer testing among Norwegian female physicians. A nation-wide comparative study.
Soc Sci Med. 2001 Jan;52(2):249-58.
Rostgaard K, Vaeth M, Holst H, Madsen M, Lynge E. Age-period-cohort modelling of breast cancer incidence in the Nordic countries.
Stat Med. 2001 Jan 15;20(1):47-61.
Wiedswang, G., Næss, A.B., Naume, B. And R. Kåresen. Micrometastasis to axillary lymph nodes and bone marrow in breast cancer patients. Breast. 2001. 10:237-242.
E. Borgen, B. Naume, J. M. Nesland, K. W. Nowels, N. Pavlak, and S. Goldbard.The use of automated microscopy for the detection of disseminated tumor cells (micrometastases) in bone marrow samples. 2001. Cytometry.46:215-221.
B. Naume, E. Borgen, G. Kvalheim, K.E., H. Qvist, E. Schlichting, R. Kåresen and J.M. Nesland. Detection of isolated tumor cells in bone marrow in early stage breast carcinoma patients. Comparison to preoperative clinical parameters and primary tumor characteristics. 2001.
Clin. Cancer Res. 7:4122-4129.
2000
Iversen BF. Eriksen L. [Mammography screening in Rogaland--the first round]. Tidsskrift for Den Norske Laegeforening. 120(27):3241-5, 2000 Nov 10.
Wang H. Hofvind SS. Thoresen SO. [A pilot project with mammography--results from the first screening round]. Tidsskrift for Den Norske Laegeforening. 120(27):3237-40, 2000 Nov 10.
Fismen K. Osland IJ. Fismen E. Borge L. Martinsen EW. Hjort P. Iversen OE. Stanghelle JK. [Rehabilitation of women with breast cancer]. Tidsskrift for Den Norske Laegeforening. 120(23):2749-54, 2000 Sep 30.
Laake K. Vu P. Andersen TI. Erikstein B. Karesen R. Lonning PE. Skovlund E. Borresen-Dale AL. Screening breast cancer patients for ATM mutations. British Journal of Cancer. 83(12):1650-3, 2000 Dec.
Tverdal A. [Breast cancer mortality in Norway and England]. [Letter] Tidsskrift for Den Norske Laegeforening. 120(22):2703, 2000 Sep 20.
Zahl PH. [Is the benefit of organized mass screening for cervix cancer and breast cancer in Norway scientifically justified?]. [Review] [22 refs] [. Review. Review, Tutorial] Tidsskrift for Den Norske Laegeforening. 120(17):2002-5, 2000 Jun 30.
Kristensen P. Andersen A. Irgens LM. Hormone-dependent cancer and adverse reproductive outcomes in farmers' families--effects of climatic conditions favoring fungal growth in grain. Scandinavian Journal of Work, Environment & Health. 26(4):331-7, 2000 Aug.
Norum J. Tranebjaerg L. Health, life and disability insurance and hereditary risk for breast or colorectal cancer. Acta Oncologica. 39(2):189-93, 2000.
Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?. Acta Oncologica. 39(1):33-9, 2000.
